HY

Hyundai ADM Bio lnc.

A contract research organization providing clinical trial services with a focus on oncology.

187660 | KO

Overview

Corporate Details

ISIN(s):
KR7187660006
LEI:
Country:
South Korea
Address:
서울특별시 종로구 새문안로5길 19, 7층 711호(당주동, 로얄빌딩), 종로구

Description

Hyundai ADM Bio Inc. is a contract research organization (CRO) that provides comprehensive services for clinical trials. The company's offerings span the full clinical development lifecycle, including regulatory affairs, medical writing, clinical operations, project management, data management, and biostatistics. A primary research focus is in oncology, where the company has developed a novel approach to address drug 'pseudo-resistance'. This strategy involves selectively targeting Cancer-Associated Fibroblasts (CAFs) to enhance the delivery and efficacy of anticancer drugs by improving their access to tumor cells. The company supports various study phases and therapeutic areas, with a specialized emphasis on advancing cancer treatment methodologies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-03 00:00
주식등의대량보유상황보고서(일반)
Korean 111.3 KB
2025-06-25 00:00
증권발행결과(자율공시)
Korean 5.6 KB
2025-06-25 00:00
합병등종료보고서(자산양수도)
Korean 17.0 KB
2025-06-25 00:00
[기재정정]주요사항보고서(타법인주식및출자증권양수결정)
Korean 45.1 KB
2025-06-20 00:00
[기재정정]주요사항보고서(타법인주식및출자증권양수결정)
Korean 47.2 KB
2025-06-17 00:00
주요사항보고서(유상증자결정)
Korean 40.5 KB
2025-06-17 00:00
[기재정정]주요사항보고서(타법인주식및출자증권양수결정)
Korean 53.4 KB
2025-06-17 00:00
투자판단관련주요경영사항(임상시험계획승인신청) (불응성 및 재발성 고형암 대상 펨브롤리주맙PenetriumTM 병용요법 …
Korean 9.9 KB
2025-06-17 00:00
[첨부추가]주요사항보고서(타법인주식및출자증권양수결정)
Korean 35.0 KB
2025-06-16 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB
2025-06-16 00:00
주주총회소집결의 (임시주주총회)
Korean 13.2 KB
2025-05-14 00:00
단일판매ㆍ공급계약체결
Korean 10.8 KB
2025-05-13 00:00
분기보고서 (2025.03)
Korean 942.2 KB
2025-05-13 00:00
투자판단관련주요경영사항(임상시험계획자진취하등) (고형암 대상"HAB-SON01" 병용요법 임상시험계획 자진취하)
Korean 11.8 KB
2025-05-09 00:00
[기재정정]사업보고서 (2024.12)
Korean 1.9 MB

Automate Your Workflow. Get a real-time feed of all Hyundai ADM Bio lnc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Hyundai ADM Bio lnc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Hyundai ADM Bio lnc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.